What is the primary goal of disease-modifying therapies in multiple sclerosis?

• A. Cure disease
• B. Reduce relapses and progression
• C. Treat acute infections
• D. Correct electrolyte abnormalities

Answer: (B)

The main idea is that disease-modifying therapies aim to slow the disease’s activity, not to cure it. In multiple sclerosis, these treatments modulate the immune system to reduce inflammatory attacks on the nervous system. By doing so, they lower the frequency of relapses and slow the accumulation of disability over time. They aren’t cures—MS can continue to progress due to neurodegenerative changes even with treatment—and they aren’t for treating infections or fixing electrolyte problems. Acute relapses are managed separately (often with short courses of high-dose steroids) rather than with disease-modifying agents.